Fig. 3From: Optimal sequencing of the first- and second-line target therapies in metastatic renal cell carcinoma: based on nationally representative data analysis from the Korean National Health Insurance SystemKaplanāMeier analysis of overall survival stratified by the first- and second-line treatments for patients after age, sex, and CCI matching. A SUN versus PAZ and (B) AXI versus CABBack to article page